

1

2

3

4 **Coverage and factor associated to the uptake of Intermittent preventive treatment for**
5 **malaria during pregnancy (IPTp) in Cameroun in 2018: an analysis from the 2018**
6 **Cameroon Demographic Health Survey data**

7

8

9

10 Dominique Guimsop Ken¹, Ange Faustine Kenmogne Talla¹, Haoua Kodji¹, Jerome Ateudjieu¹

11

12

13 ¹Departement of public health, Faculty of Medicine and Pharmaceutical Sciences, University
14 of Dschang, Dschang, Cameroon

15

16

17 * Corresponding author

18 E-mail: dk.guimsop@outlook.com

19 Abstract

20 Malaria in pregnancy is a major public health issue, contributing to significantly
21 increasing mother and children mortality and morbidity. Intermittent preventive treatment of
22 malaria using Sulfadoxine-Pyrimethamine (IPTp-SP) is one of the key interventions
23 recommended by WHO and in Cameroon to reduce the morbidity of Malaria in Pregnancy. The
24 present study aims to assess the distribution and determinants of poor uptake of IPTp-SP (< 3
25 doses) among pregnant women in Cameroon.

26 We conducted a secondary analysis of data extracted from the Cameroun Demographic
27 Health Survey conducted in 2018. Data were collected using a questionnaire administered in
28 face to face to mothers with at least one child under 5, selected using a 2-stage stratified
29 sampling process. Frequencies of mothers exposed to less than 3 doses of IPTp-SP were
30 estimated with a 95% CI. A case-control design was used to assess the association between key
31 suspected determinants and being exposed to less than 3 doses of IPTp-SP. This was measured
32 by estimating crude and adjusted Odd-Ratios (ORs).

33 A total of 13527 childbearing age women were interviewed, of which 5528 (40.9%)
34 met our selection criteria. Among those, 845 (15.3%) had not attended any Antenatal care
35 (ANC) visit, 1109 (20%) had attended 1 to 3 visits, 3379 (61.1%) had attended 4 to 7 visits and
36 only 195 (3.5%) had attended at least 8 visits. In all, 3398 (61.5%, CI: 60.2-62.8) had received
37 less than 3 doses of IPTp-SP. Maternal age below 26 years (aOR=1.17, CI: 1.01-1.35),
38 residence in an area of lower malaria endemicity (aOR=1.26, CI: 1.00-1.58), residence in the
39 Sahelian regions (aOR=5.81, CI: 2.46-13.69), and having attended less than 4 ANC visits
40 (aOR=1.30, CI: 1.08-1.57) were predictors of poor uptake of IPTp-SP. Conversely, residence
41 in major cities (aOR=0.65, CI: 0.50-0.84), having attended a first ANC visit at 3 months or less
42 of pregnancy (aOR=0.66, CI: 0.57-0.78) and having been followed on ANC by a medical doctor

43 (aOR=0.22, CI: 0.13-0.35), were preventing factors for poor uptake of IPTp3+. Highest level
44 of education (aOR= 1.10, CI: 0.90-1.32) was not found associated with the uptake of IPTp-SP.

45 Therefore, only a third of pregnant women in Cameroon take an optimal dose of IPTp-
46 SP. This proportion vary widely with the place of residence, being significantly low in the
47 Sahelian regions. Interventions to address identified determinants of low coverage of IPTp-SP
48 like maternal age below 26 years, ANC characteristics or being resident of area with lower
49 malaria endemicity ought to be tested.

50

51

52 **Introduction**

53 Malaria, caused in humans by five species of *Plasmodium*, remains one of the most
54 widespread infectious diseases. The heavy burden is mainly related to *Plasmodium falciparum*
55 and *Plasmodium vivax*. It threatens nearly half of the world's population, resulting in 229
56 million cases and 409.000 deaths in 2019, Africa accounting for over 90% of cases [1]. Malaria
57 is significantly known to increase the risk of maternal and fetal anemia, abortion, low birth
58 weight, and neonatal death [2-5]. To reduce the burden of the disease, efforts are channeled
59 into 3 main strategies: Intermittent Preventive Treatment in pregnancy with Sulfadoxine-
60 Pyrimethamine (IPTp-SP), use of insecticide-treated nets, and effective case management in all
61 areas of moderate to severe transmission [6]. IPTp-SP policy recommends that each pregnant
62 woman receive at least three doses of Sulfadoxine-Pyrimethamine (SP) throughout her
63 pregnancy, each at least one month apart, which can be safely administered from 13 weeks to
64 delivery [7, 8].

65 Despite implemented interventions, the 3 doses IPTp-SP coverage in 2020 was 34%
66 overall in the 33 countries that adopted the preventive measure [1]. The poor performance can

67 be explained by limited access to healthcare, poor training of health care providers, stock-outs
68 of the drugs, maternal and pregnancy-related factors as level of education and multigravidity
69 among others [9-12].

70 In Cameroon, the Ministry of Health adopted a new policy of chemoprevention of
71 malaria since May 2002 as part of ANC through the use of chloroquine, which was later
72 replaced in January 2004 by IPTp-SP following related WHO recommendations [13]. Available
73 literature estimated in 2018 the 3 doses coverage of IPTp-SP among pregnant women in
74 Cameroon between 23.5% and 54.9% depending on socio-demographic characteristics,
75 antenatal care performance, and study type [9, 14]. These figures lag clearly behind the 80%
76 coverage rate targeted by the country for 2023. No study has been conducted to understand
77 limitation of health care systems in achieving its objectives. While such finding would help
78 policymakers in their effort to improve the effectiveness of actual strategies or propose new
79 ones. The present study evaluated the distribution of poor uptake of ≥ 3 doses of IPTp-SP
80 among pregnant women in Cameroon and assessed its determinants.

81

82 **Methodology**

83 **Study design and setting**

84 We conducted a secondary data analysis of the 2018 Cameroon Demographic and
85 Health Survey (DHS) [14]. The data were collected from a cross-sectional household-based
86 survey targeting 22 territorial units of Cameroon including 10 regions (each parted into their
87 respective urban and rural areas) and the two major cities of the country. One of the areas
88 affected by the ongoing socio-political crisis was excluded. Household were selected by
89 stratified cluster random sampling process and in each visited household the data were collected
90 using a face-to-face administered questionnaire.

91

92

93 **Study population**

94 The target population was all women aged 15–49 years residing in the selected cluster
95 and biological mother of a living child aged less than at the day the selected household is
96 visited.

97

98 **Participants extraction from the data base**

99 From the variable “woman of childbearing age”, we deducted the variable “mother of
100 a under 5 years old child” by coding. From those selected we excluded participants who did
101 not have recorded data on the age of the child, those who did not have data on whether or not
102 they attended ANC visits and those did not have data on whether or not they took sulphadoxine
103 pyrimethamine during the pregnancy of the child (Fig 1).

104 **Fig 1. Flow diagram of sample selection from CDHS 2018 data.**

105

106

107 **Variable of interest**

108 Data were extracted for analysis based on variables that were theoretically and
109 empirically linked to the uptake of ≥ 3 doses of IPTp-SP as follow: (a) the dependent variable
110 was the number of women who had received less than three doses of IPTp-SP (Poor uptake of
111 ≥ 3 doses of IPTp-SP) ; (b) Independent variables comprised woman’s age, stay in the place of
112 residence, woman’s highest educational level, religion, literacy, wealth, health insurance
113 coverage, occupational status, matrimonial status, partner’s highest level of education, region,
114 area of residence, area’s malaria prevalence, wanted pregnancy, parity, history of a terminated

115 pregnancy, ANC highest attendant, number of ANC visits. Variables regarding pregnancy and
116 prenatal care were relative to the most recent live birth.

117

118 **Data management**

119 Data extraction, grooming, and analysis were done using IBM SPSS Statistics version
120 26 (International business machines corp., New York, USA).

121 The complex sampling design of the survey was taken into account by using the
122 “Complex samples” functionality of IBM SPSS for the analyses, and except specified
123 otherwise, only weighted data were presented in our results.

124

125 **Statistical analysis**

126 Categorical variables were summarized as frequencies and proportions. In analytic
127 analysis, the Rao-Scott correction to Chi-square test was used to compare the distribution of
128 the independent variables between the two levels of our dependent variable. Bivariate logistic
129 regression was then used after all dependent variables were dichotomized, to measure the
130 association with our independent variable. Dependents that had an association with the outcome
131 significant at $p < 0.05$ were selected for the multivariate logistic regression model. This
132 estimated adjusted odds ratio (aOR) and their significance, controlling for the effect of other
133 dependent variables. Collinearity was checked using Variance inflation factors (VIFs)
134 calculation. Finally, substantive cross-level interactions among our dependents were explored,
135 and only one was found significant, which was kept in the model. The level of significance
136 used was 5% (0.05), two-tailed.

137

138 Ethical consideration

139 The Cameroon DHS protocol, including measuring procedures and biological tests, was
140 reviewed and approved by the Cameroonian ministry of health National ethical committee for
141 research and human health (CNERSH) and Inner-City Fund (ICF) Institutional Review Board.
142 Informed consent for the survey was obtained from each respondent before each interview.
143 Permission to access the Cameroonian DHS 2018 survey dataset for the present study was
144 obtained from the Demographic and Health Surveys (DHS) Program. Surveyors maintained
145 confidentiality by an anonymization technique attributing a code to every case. The accessed
146 data set was kept on a password-secured computer.

147

148

149 Results

150 Characteristics of the population

151 We included 5528 participants from the database, with almost half (48.1%, n=2657)
152 aged between 25 and 35 years old and 44.5% (n=2455) having attended at least secondary
153 school. About half (52.6%, n=2911) of the women lived in rural areas, and they seem to be
154 fairly distributed across wealth classes. Overall, 61.5% (n = 3398) of the study population had
155 taken less than three doses of IPTp-SP (Table 1).

156 **Table 1. Socio-demographic and environmental characteristics of participants and**
157 **comparison between those who took less than 3 doses of IPTp-SP and others (N=5528)**

| Variables | IPTp-SP uptake, n (%) | | | Rao-Scott F(df1, df2) | p |
|--------------------|-----------------------|--------------------|--------------------|-----------------------|-------|
| | Total N=5528 | <3 doses n=3398 | 3+ doses n=2130 | | |
| Age groups (years) | | | | | |
| 15-19 | 521 (9.4) | 333 (9.8) | 188 (8.8) | 0.93 (4.53, 1846.71) | 0.457 |
| 20-24 | 1205 (21.8) | 760 (22.4) | 445 (20.9) | . | |
| 25-29 | 1496 (27.1) | 918 (27.0) | 578 (27.1) | | |
| 30-34 | 1161 (21.0) | 703 (20.7) | 459 (21.5) | | |

| | | | | | |
|---|-------------|-------------|-------------|-----------------------|--------|
| 35-39 | 727 (13.1) | 421 (12.4) | 305 (14.3) | | |
| 40-49 | 416 (7.5) | 262 (7.7) | 155 (7.3) | | |
| Stay in the place of residence | | | | | |
| Visitor | 121 (2.2) | 79 (2.2) | 42 (2.0) | 0.26 (2.83, 1158.50) | 0.844 |
| 0-19 years | 3454 (62.5) | 2119 (62.4) | 1334 (62.6) | | |
| 20-40] years | 219 (4.0) | 140 (4.1) | 79 (3.7) | | |
| Always | 1734 (31.4) | 1060 (31.2) | 674 (31.7) | | |
| Highest educational level | | | | | |
| No formal education | 1425 (25.8) | 996 (29.3) | 429 (20.2) | 16.24 (2.77, 1130.29) | <0.001 |
| Primary | 1647 (29.8) | 1058 (31.1) | 590 (27.7) | | |
| Secondary | 2121 (38.4) | 1185 (34.9) | 936 (43.9) | | |
| Higher | 334 (6.1) | 160 (4.7) | 175 (8.2) | | |
| Religion | | | | | |
| Animism/other | 212 (3.8) | 145 (4.3) | 67 (3.1) | 4.70 (1.97, 805.91) | 0.010 |
| Christian | 3786 (68.5) | 2246 (66.1) | 1540 (72.3) | | |
| Muslim | 1530 (27.7) | 1007 (29.6) | 523 (24.6) | | |
| Illiterate | 2016 (36.5) | 1391 (40.9) | 625 (29.3) | 30.88 (1.0, 408.0) | <0.001 |
| Combined wealth index | | | | | |
| Poorest | 1111 (20.1) | 779 (22.9) | 331 (15.5) | 22.38 (3.75, 1531.02) | <0.001 |
| Poorer | 1215 (22) | 842 (24.8) | 374 (17.5) | | |
| Middle | 1135 (20.5) | 734 (21.6) | 401 (18.8) | | |
| Richer | 1100 (19.9) | 587 (17.2) | 514 (24.1) | | |
| Richest | 967 (17.5) | 457 (13.5) | 510 (23.9) | | |
| Health insurance coverage | 99 (1.8) | 45 (1.3) | 54 (2.5) | 7.62 (1.0, 408.0) | 0.006 |
| Current occupation | 3769 (68.3) | 2306 (67.9) | 1463 (68.7) | 0.21 (1.0, 408.0) | 0.650 |
| Ever in union | 4448 (80.5) | 2767 (81.4) | 1681 (78.9) | 3.74 (1.0, 408.0) | 0.054 |
| Partner's highest level of education, secondary + | 3636 (65.8) | 2336 (68.8) | 1299 (61) | 21.87 (1.0, 408.0) | <0.001 |
| Region | | | | | |
| Sahelian regions | 2025 (36.6) | 1326 (39) | 699 (32.8) | 20.0 (1.94, 793.42) | <0.001 |
| Southern regions | 2528 (45.7) | 1611 (47.4) | 917 (43.0) | | |
| Douala/Yaounde | 975 (17.6) | 461 (13.6) | 515 (24.2) | | |
| Rural area of residence | 2911 (52.6) | 2000 (58.9) | 911 (42.8) | 48.75 (1, 41) | <0.001 |
| Area's malaria prevalence (%) | | | | | |
| 0-9 | 1008 (18.2) | 560 (16.5) | 448 (21) | 508.0 (2.82, 1150.09) | 0.002 |
| 10-19 | 1717 (31.1) | 1061 (31.2) | 656 (30.8) | | |
| 20-29 | 1529 (27.7) | 907 (26.7) | 622 (29.2) | | |
| 30 + | 1274 (23.1) | 870 (25.6) | 404 (19) | | |

158 IPTp-SP, Intermittent preventive treatment in pregnancy with Sulphadoxine pyrimethamine

159

160 Up to 845 (15.3 %) women did not attend any ANC visit. Among the 3574 (64.6 %) women

161 who attended the recommended number of visits, 1686 (47.2%) took ≥ 3 doses of IPTp-SP (Fig

162 2).

163

164 **Fig 2. Proportion of uptake of ≥ 3 doses of IPTp-SP by number of ANC visits.**

165

166

167 **Socio-demographic characteristics of participants and uptake of**

168 **≥ 3 doses of IPTp-SP**

169 There was no association between the stay in the place of residence and uptake of IPTp-

170 SP ($p = 0.844$). A lower proportion of women with poor uptake of IPTp-SP had attended

171 secondary education compared to those who took more doses (39.6% vs. 52.1%, $p \leq 0.001$).

172 Furthermore, there were more illiterate among participants with poor uptake of IPTp-SP (40.9%

173 vs. 29.3%, $p < 0.001$). Only 1.8% ($n = 99$) of pregnant women were covered by some health

174 insurance; these were more represented among those who took ≥ 3 doses of IPTp-SP ($p = 0.006$).

175 A lower proportion of women with poor uptake of IPTp-SP had ever been in union with a

176 partner than women who received more doses (78.9% vs. 81.4%), though this association was

177 not statistically significant ($p=0.054$). Moreover, more women among those with poor uptake

178 of IPTp-SP had a partner with a secondary or more level of education (68.8% vs. 61%, $p <$

179 0.001). The Sahelian regions were more represented among those who took less than

180 recommended 3 doses of IPTp-SP (39% vs. 32.8%) compare to those who took recommended

181 doses. The distribution of women across areas with varying levels of endemicity was

182 statistically different according to the uptake of IPTp-SP ($p = 0.002$).

183

184 **Obstetrical history of participants and uptake of ≥ 3 doses of**

185 **IPTp-SP**

186 Fewer women among those with poor uptake of IPTp-SP had a parity below 6 than among
 187 those who took more doses ($p = 0.033$). Similarly, fewer women with poor uptake of IPTp-SP
 188 had a history of terminated pregnancy ($p = 0.022$). There was a significant association between
 189 highest ANC attendant and uptake of IPTp-SP ($p < 0.001$), with a greater proportion of women
 190 among those with poor uptake of IPTp-SP having received no care (24% vs. 1.4%) and a lesser
 191 proportion having been cared by a doctor (22.2 vs. 34.9). Only 41.1 % of pregnant women had
 192 attended their first ANC visit before the fourth month of pregnancy; those were more
 193 represented among women who took recommended doses of IPTp-SP (54.5% vs. 32.8%, $p <$
 194 0.001). The majority of women (61.1%) had attended 4 to 7 ANC visits. The association
 195 between the number of ANC attended and the uptake of IPTp-SP was also significant ($p <$
 196 0.001) and a greater proportion of the women who took recommended doses had attended over
 197 4 visits (79.2% vs. 55.5%). (Table 2)

198 **Table 2. Obstetrical history and comparison between participants who took less than 3**
 199 **doses of IPTp-SP and others (N=5528)**

| Variables | Total N=5528 | IPTp-SP uptake, n (%) | | Rao-Scott F(df1, df2) | p |
|--|-----------------|-----------------------|--------------------|-----------------------|--------|
| | | <3 doses n=3398 | 3+ doses n=2130 | | |
| Wanted pregnancy | 4250 (76.9) | 2585 (76.1) | 1665 (78.2) | 1.81 (1, 408) | 0.180 |
| Parity ≤ 5 | 4432 (80.2) | 2682 (78.9) | 1750 (82.1) | 4.56 (1, 408) | 0.033 |
| History of terminated pregnancy | 1023 (18.5) | 584(17.2) | 439 (20.6) | 5.29 (1, 408) | 0.022 |
| ANC highest attendant | | | | | |
| No care | 845 (15.3) | 816 (24) | 29 (1.4) | 93.30 (2.75, 1123.61) | <0.001 |
| Doctor | 1495 (27) | 753 (22.2) | 742 (34.9) | | |
| Nurse/midwife | 3012 (54.5) | 1734 (51) | 1278 (60) | | |
| Others | 176 (3.2) | 95 (2.8) | 80 (3.8) | | |
| 1 st ANC visit before/at 3 months | 2274 (41.1) | 1114 (32.8) | 1160 (54.5) | 172.05 (1, 408) | <0.001 |
| Number of ANC visits | | | | | |
| 0 | 845 (15.3) | 816 (24) | 29 (1.4) | 67.40 (4.61, 1880.81) | <0.001 |
| 1 | 83 (1.5) | 59 (1.7) | 24 (1.1) | | |
| 2 | 233 (4.2) | 167 (4.9) | 66 (3.1) | | |

| | | | | | |
|-------|-------------|-------------|-------------|--|--|
| 3 | 793 (14.3) | 469 (13.8) | 324 (15.2) | | |
| 4 - 7 | 3379 (61.1) | 1792 (52.7) | 1586 (74.5) | | |
| 8 + | 195 (3.5) | 95 (2.8) | 100 (4.7) | | |

200 IPTp-SP, Intermittent preventive treatment in pregnancy with Sulphadoxine pyrimethamine;
201 ANC, Antenatal care.

202

203 **Determinants of the uptake of less than three doses of IPTp-SP**

204 Table 3 shows the results of logistic regression analyses. It indicates that independent predictors
205 of poor uptake of IPTp-SP were age below 26 ($p = 0.038$), residing in an area of lower
206 endemicity ($p = 0.047$), in the Sahelian regions ($p < 0.001$) and having attended less than 4
207 ANC visits ($p = 0.006$). Women residing in large cities ($p = 0.001$), who attended a first ANC
208 visit at 3 months or less of pregnancy ($p < 0.001$) and had been followed on ANC by a medical
209 doctor ($p < 0.001$), were less likely to receive less than 3 doses of IPTp-SP than those residing
210 in the southern regions, who attended first ANC visit latter and followed on by other health
211 care workers. Last, the effect of the cross-level interaction between the ANC highest attendant
212 and the Sahelian regions was positive and statistically significant ($p < 0.001$), indicating that
213 the effect of the ANC highest attendant on the risk of a woman receiving less than
214 recommended doses is conditional on whether the woman resides in the Sahelian regions;
215 notably, women attended by medical doctors in the Sahelian regions had an even lesser risk of
216 poor IPTp-SP uptake than those residing in the Southern regions (Fig 3).

217 **Determinants of the uptake of less than 3 doses of IPTp-SP by pregnant women**

| Variables | IPTp-SP uptake, n (%) | | OR (95% CI) | aOR (95% CI) | p |
|---------------------------|-----------------------|--------------------|------------------|------------------|--------------|
| | <3 doses n=3398 | 3+ doses n=2130 | | | |
| Age (years) | | | | | |
| 0-25 | 1323.74 (39.0) | 755.34 (35.5) | 1.16 (1.00-1.33) | 1.17 (1.01-1.34) | 0.038 |
| 26-49 | 2074.30 (61.0) | 1374.76 (64.5) | 1 | | |
| Highest educational level | | | | | |
| No/ primary | 2053.30 (60.4) | 1019.06 (47.8) | 1.66 (1.43-1.93) | 1.10 (0.90-1.32) | 0.378 |
| Secondary, + | 1344.71 (39.6) | 1111.03 (52.2) | 1 | | |

| | | | | | |
|---|----------------|----------------|------------------|-------------------|------------------|
| Christian | | | | | |
| Yes | 2246.18 (66.1) | 1539.66 (72.3) | 0.74 (0.61-0.91) | 1.00 (0.78-1.29) | 0.971 |
| No | 1151.86 (33.9) | 590.43 (27.7) | 1 | | |
| Combined wealth index | | | | | |
| Poor | 1620.91 (47.7) | 704.89 (33.1) | 1.84 (1.54-2.20) | 1.08 (0.87-1.33) | 0.481 |
| Middle to rich | 1777.13 (52.3) | 1425.21 (66.9) | 1 | | |
| Covered by health insurance | | | | | |
| Yes | 44.88 (1.3) | 53.802 (2.5) | 0.51 (0.32-0.83) | 0.76 (0.48-1.21) | 0.252 |
| No | 3353.15 (98.7) | 2076.29 (97.5) | 1 | | |
| Ever in union | | | | | |
| Yes | 2766.95 (81.4) | 1680.74 (78.9) | 1.17 (0.99-1.37) | 1.06 (0.86-1.30) | 0.570 |
| No | 631.09 (18.6) | 449.36 (21.1) | 1 | | |
| Partner's highest level of education, secondary + | | | | | |
| Yes | 1061.65 (31.2) | 830.97 (39.0) | 1.41 (1.21-1.62) | 0.91 (0.77-1.10) | 0.330 |
| No | 2336.39 (68.8) | 1299.12 (61.0) | 1 | | |
| Region | | | | | |
| Sahelian regions | 1326.32 (39.0) | 698.56 (32.8) | 2.12 (1.66-2.70) | 5.72 (2.41-13.58) | <0.001 |
| Douala/Yaounde | 460.75 (13.6) | 514.64 (24.2) | 1.96 (1.57-2.45) | 0.64 (0.50-0.84) | 0.001 |
| Southern regions | 1610.96 (47.4) | 916.89 (43.0) | 1 | | |
| Type of Place of residence | | | | | |
| Rural | 1999.90 (58.9) | 910.65 (42.8) | 1.91 (1.59-2.30) | 1.22 (1.09-1.56) | 0.108 |
| Urban | 1398.14 (41.1) | 1219.44 (57.2) | 1 | | |
| Malaria Prevalence (%) | | | | | |
| 0-19 | 1620.75 (47.7) | 1104.24 (51.8) | 0.85 (0.70-1.02) | 1.26 (1.00-1.58) | 0.047 |
| 20 + | 1777.29 (52.3) | 1025.85 (48.2) | 1 | | |
| Wanted pregnancy | | | | | |
| Yes | 3244.12 (95.5) | 2035.81 (95.6) | 0.89 (0.74-1.05) | 1.02 (0.72-1.46) | 0.892 |
| No | 153.92 (4.5) | 94.28 (4.4) | 1 | | |
| Parity ≤ 5 | | | | | |
| Yes | 2681.88 (78.9) | 1749.78 (82.1) | 0.81 (0.67-0.98) | 0.95 (0.76-1.19) | 0.892 |
| No | 716.16 (21.1) | 380.32 (17.9) | 1 | | |
| Ever had a prematurely terminated pregnancy | | | | | |
| Yes | 584.34 (17.2) | 438.79 (20.6) | 0.80 (0.66-0.96) | 0.91 (0.74-1.11) | 0.377 |
| No | 2813.70 (82.8) | 1691.31 (79.4) | 1 | | |
| ANC highest attendant | | | | | |
| Medical doctor | 2576.04 (75.8) | 2100.26 (98.6) | 0.04 (0.03-0.06) | 0.22 (0.13-0.36) | <0.001 |
| Other | 822 (24.2) | 29.84 (1.4) | 1 | | |
| 1 st ANC visit before/at 3 months | | | | | |
| Yes | 1114.99 (32.8) | 1160.07 (54.5) | 0.41 (0.35-0.46) | 0.67 (0.57-0.78) | <0.001 |
| No | 2283.05 (67.2) | 970.02 (45.5) | 1 | | |
| Number of ANC visits | | | | | |
| < 4 | 1510.93 (44.5) | 443.38 (20.8) | 3.05 (2.53-3.66) | 1.30 (1.08-1.57) | 0.006 |

| | | | | | |
|---|----------------|----------------|---|----------------|------------------|
| ≥ 4 | 1887.11 (55.5) | 1686.71 (79.2) | 1 | | |
| ANC highest attendant: medical doctor <i>by</i> Sahelian regions* | | | | -2.345 (0.468) | <0.001 |

218 IPTp-SP, Intermittent preventive treatment in pregnancy with Sulphadoxine pyrimethamine;

219 ANC, Antenatal care.

220 * Interaction effect (s.e)

221

222

223 **Fig 3. Cross-level interaction (ANC highest attendant x Sahelian regions region) plot.**

224

225

226 Discussion

227 Since 2004 in Cameroon, IPTp-SP stands as a core strategy for the prevention of malaria in
 228 pregnancy. We aimed to determine the proportion of, and identify the factors associated with
 229 poor uptake of IPTp-SP. We found a high proportion (61.5%) of childbearing age women took
 230 less than the recommended ≥ 3 doses of IPTp-SP during their most recent pregnancy. Factors
 231 associated comprised younger maternal age (aOR=1.17, CI: 1.01-1.35), residence in an area of
 232 lower endemicity (aOR=1.26, CI: 1.00-1.58), residence in the Sahelian regions (aOR=5.81, CI:
 233 2.46-13.69), and having attended less than 4 ANC visits (aOR=1.30, CI: 1.08-1.57); as well as
 234 residence in large cities (aOR=0.65, CI: 0.50-0.84), having attended a first ANC visit at 3
 235 months or less of pregnancy (aOR=0.66, CI: 0.57-0.78) and having been followed on ANC by
 236 a medical doctor (aOR=0.22, CI: 0.13-0.35).

237 In line with the Rollback malaria (RBM) Partnership, Cameroon's ministry of health targets at
 238 80% the 3 doses coverage of IPTp-SP by 2023 [15]. Though the found 38.5% are a big
 239 improvement from the 12.9% in 2011 [10]; the country still has some way to go. However, a

240 2013 cross-country DHS analytical study found the ≥ 3 doses coverage of IPTp-SP varying
241 between 0.3% to 43% in sub-Saharan Africa, thus ranking Cameroon among the “high IPTp
242 coverage countries”. Countries with reported lower ≥ 3 doses coverage of IPTp-SP seem
243 characterized by greater malaria funding, unclear or tardily adopted relevant policy, lower
244 levels of ANC attendance with greater proportion of missed IPTp-SP administration
245 opportunities, and general healthcare system issues (as stock-outs or user fees) [16-19].

246 In Cameroon as in most sub-Saharan African countries, IPTp-SP distribution was mainly
247 channeled through the ANC program and has become an integral part of it. It ensues from this,
248 as we could find in our study, that women who have their 1st contact with health care providers
249 not early enough and who attend a lower number of subsequent visits are less likely to receive
250 the recommended doses. This concords with studies showing early timing of initial ANC visit
251 to improve uptake of IPTp-SP [17, 20-22]; and those demonstrating an increasing probability
252 of completing IPTp-SP doses with the number of attended ANC visits [10, 11, 23-25].
253 Nonetheless, only 47.2% of women having attended over 4 visits did take recommended doses.
254 This depicts an important frequency of missed opportunities for IPTp-SP administration.
255 Barriers standing between ANC and uptake of ≥ 3 doses of IPTp-SP can be broadly grouped
256 into health system-related factors, ANC attendant related factors, maternal related factors. ANC
257 attendant qualification, as found here, can therefore determine the uptake of ≥ 3 doses of IPTp-
258 SP, with doctors generally providing better care, when compared with other attendants. A study
259 in the northwest reported up to 35.9% of health providers had received no training on IPT and
260 about 30% not knowing when to start the preventive treatment [9], aligning with numerous
261 studies finding a poor general knowledge regarding intermittent preventive treatment among
262 healthcare providers [17].

263 Researchers equally report numerous maternal-related factors as predictors of poor IPTp3
264 uptake. We found younger age to be associated with poor uptake of ≥ 3 doses of IPTp-SP. Age

265 is a rather unsettled factor across countries [17]. Our finding is however consistent with a study
266 in the South-west region of Cameroon, though not statistically significant, supporting that
267 younger women were seemingly showing lower interest for IPTp-SP [12]. A Nigerian study
268 found similar results [21]. Younger women, with less maternal experience, might overlook the
269 subtle symptoms of malaria in pregnancy, or underestimate its effects, thus the lower interest
270 for the preventive treatment.

271 Our study furthermore shows that women residing in areas of higher endemicity had a higher
272 risk of not taking the three or more recommended doses of IPTp-SP. This supports the result of
273 the DHS multi-country analytical study showing an inverse association between the level of
274 malaria transmission and the uptake of ≥ 3 doses of IPTp-SP [24]. A potential explanation would
275 be an increase in drug shortage or service overwhelming from the elevated demand or the
276 dodging of preventive doses because of recent treatment received for frequent infections. The
277 efficiency principle however calls for a better consideration of exposure when planning the
278 health initiative.

279 Also, women residing in the Sahelian regions of the country were found more likely to not
280 taking the recommended ≥ 3 doses of IPTp-SP compare to those residing in the southern
281 regions; and an opposite association was found for women residing in the great cities (Douala/
282 Yaounde). The Sahelian regions contains 3 of the 5 regions where women report greater issues
283 with healthcare access [14]. The low level of socio-economic development in the region equally
284 renders healthcare delivery deficient, with the Far North, for example, only containing 8% of
285 Cameroonian doctors despite its 18% of the population [26]. These also give us a glimpse of
286 how the potential gain in women completing their doses of IPTp-SP from an added medical
287 doctor as ANC attendant would be significantly greater when added in the Sahelian regions
288 than in the southern regions; as our cross-level interaction term showed.

289

290

291 **Conclusion**

292 Despite significant improvement with time, coverage of ≥ 3 doses of IPTp-SP in Cameroon is
293 still low. We identified maternal age, malaria endemicity, place of residence, number of ANC
294 visits attended, timing of first ANC visit, and ANC attendant (which had its effect significantly
295 modified when residing in the Sahelian regions) as important predictors of the uptake of ≥ 3
296 doses of IPTp-SP. While pregnant women should be encouraged to strictly follow the ANC
297 policy recommendations, further studies should be carried to evaluate ANC attendant related
298 factors that could explain the elevated proportion of missed opportunities for IPTp-SP
299 administration. Furthermore, the finding of lower IPTp-SP uptake in area of higher endemicity
300 calls for better management of available resources. Greater attention shall be given to the
301 Sahelian regions, where policymakers shall first comprehend the specific obstacles to both
302 healthcare access and service delivery and develop strategies that overcome these obstacles.

303 **Acknowledgments**

304 We gratefully thank *The DHS Program* team, who has granting us access to the 2018 Cameroon
305 Demographic Health Survey database.

306

307 **References**

- 308 1. World Health Organization. World malaria report 2020: 20 years of global progress and
309 challenges. Geneva: World Health Organisation; 2020. Available from:
310 <https://apps.who.int/iris/rest/bitstreams/1321872/retrieve>. Accessed 27 Feb 2021.
- 311 2. Cottrell G, Moussiliou A, Luty AJF, Cot M, Fievet N, Massougbodji A, et al.
312 Submicroscopic Plasmodium falciparum Infections Are Associated With Maternal Anemia,
313 Premature Births, and Low Birth Weight. *Clinical Infectious Diseases*. 2015;60(10):1481-8.
- 314 3. Desai M, ter Kuile FO, Nosten F, McGready R, Asamo K, Brabin B, et al.
315 Epidemiology and burden of malaria in pregnancy. *The Lancet Infectious diseases*.
316 2007;7(2):93-104.
- 317 4. Hartman TK, Rogerson SJ, Fischer PR. The impact of maternal malaria on newborns.
318 *Annals of tropical paediatrics*. 2010;30(4):271-82.
- 319 5. Yimam Y, Nateghpour M, Mohebal M, Abbaszadeh Afshar MJ. A systematic review
320 and meta-analysis of asymptomatic malaria infection in pregnant women in Sub-Saharan
321 Africa: A challenge for malaria elimination efforts. *PLOS ONE*. 2021;16(4):e0248245.
- 322 6. World Health Organization. Global technical strategy for malaria 2016-2030. Geneva:
323 World Health Organisation; 2015. Available from:
324 <https://apps.who.int/iris/handle/10665/176712>. Accessed 27 Feb 2021.
- 325 7. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for
326 preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or
327 no treatment. *The Cochrane database of systematic reviews*. 2014;2014(10):Cd000169.
- 328 8. World Health Organization. Intermittent preventive treatment of malaria in pregnancy
329 using sulfadoxine-pyrimethamine (IPTp-SP): updated WHO policy recommendation. Geneva:

- 330 World Health Organization; 2012 2012. Contract No.: WHO/HTM/GMP.2012.05. Available
331 from: <https://apps.who.int/iris/handle/10665/337990>. Accessed 27 Feb 2021.
- 332 9. Diengou NH, Cumber SN, Nkfusai CN, Mbinyui MS, Zennobia VV, Bede F, et al.
333 Factors associated with the uptake of intermittent preventive treatment of malaria in pregnancy
334 in the Bamenda health districts, Cameroon. PAMJ. 2020;35(42).
- 335 10. Dionne-Odom J, Westfall AO, Apinjoh TO, Anchang-Kimbi J, Achidi EA, Tita ATN.
336 Predictors of the use of interventions to prevent malaria in pregnancy in Cameroon. Malaria
337 Journal. 2017;16(1):132.
- 338 11. Leonard N, Eric FB, Judith AK, Samuel W. Factors associated to the use of insecticide
339 treated nets and intermittent preventive treatment for malaria control during pregnancy in
340 Cameroon. Archives of public health = Archives belges de sante publique. 2016;74:5.
- 341 12. Takem EN, Achidi EA, Ndumbe PM. Use of intermittent preventive treatment for
342 malaria by pregnant women in Buea, Cameroon. Acta tropica. 2009;112(1):54-8.
- 343 13. Republique du Cameroun. Enquête Démographique et de Santé du Cameroun 2004.
344 Yaoundé, Cameroun: Institut National de la Statistique (INS) Jun 2005.
- 345 14. Republique du Cameroun. Enquête Démographique et de Santé du Cameroun 2018.
346 Yaoundé, Cameroun: Institut National de la Statistique (INS) Fev 2020.
- 347 15. Republic of Cameroon. National Strategic Malaria Control Plan 2019-2023. Yaounde,
348 Cameroon: Ministry of public health Oct 2019. Available from: [https://pnlp.cm/plan-](https://pnlp.cm/plan-strategique/)
349 [strategique/](https://pnlp.cm/plan-strategique/). Accessed 12 Mar 2021.
- 350 16. Andrews KG, Lynch M, Eckert E, Gutman J. Missed opportunities to deliver
351 intermittent preventive treatment for malaria to pregnant women 2003–2013: a systematic
352 analysis of 58 household surveys in sub-Saharan Africa. Malaria Journal. 2015;14(1):521.

- 353 17. Hill J, Hoyt J, van Eijk AM, D'Mello-Guyett L, Ter Kuile FO, Steketee R, et al. Factors
354 affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-
355 Saharan Africa: a systematic review and meta-analysis. *PLoS Med.* 2013;10(7):e1001488.
- 356 18. Van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, et al. Coverage
357 of intermittent preventive treatment and insecticide-treated nets for the control of malaria
358 during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data,
359 2009-11. *The Lancet Infectious diseases.* 2013;13(12):1029-42.
- 360 19. World Health Organization. World malaria report 2016. Geneva: World Health
361 Organisation; 2016. Available from: <https://apps.who.int/iris/rest/bitstreams/1321872/retrieve>.
362 Accessed 27 Feb 2021.
- 363 20. Hill J, Dellicour S, Bruce J, Ouma P, Smedley J, Otieno P, et al. Effectiveness of
364 antenatal clinics to deliver intermittent preventive treatment and insecticide treated nets for the
365 control of malaria in pregnancy in Kenya. *PloS one.* 2013;8(6):e64913-e.
- 366 21. Iliyasu Z, Gajida AU, Galadanci HS, Abubakar IS, Baba AS, Jibo AM, et al. Adherence
367 to intermittent preventive treatment for malaria in pregnancy in urban Kano, northern Nigeria.
368 *Pathog Glob Health.* 2012;106(6):323-9.
- 369 22. Sangho O, Tounkara M, Whiting-Collins LJ, Beebe M, Winch PJ, Doumbia S.
370 Determinants of intermittent preventive treatment with sulfadoxine–pyrimethamine in pregnant
371 women (IPTp-SP) in Mali, a household survey. *Malaria Journal.* 2021;20(1):231.
- 372 23. Azizi SC. Uptake of intermittent preventive treatment for malaria during pregnancy
373 with Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health
374 Organization policy: an analysis of demographic and health survey 2015–2016. *BMC Public*
375 *Health.* 2020;20(1):335.

- 376 24. Florey L. Preventing Malaria during Pregnancy in Sub-Saharan Africa: Determinants
377 of Effective IPTp Delivery. Calverton, Maryland, USA: ICF International; 2013 Sep. Available
378 from: <https://dhsprogram.com/pubs/pdf/AS39/AS39.pdf>. Accessed 27 Feb 2021.
- 379 25. Olugbade OT, Ilesanmi OS, Gubio AB, Ajayi I, Nguku PM, Ajumobi O. Socio-
380 demographic and regional disparities in utilization of intermittent preventive treatment for
381 malaria in pregnancy - Nigeria demographic health survey 2013. The Pan African medical
382 journal. 2019;32(Suppl 1):13.
- 383 26. Bove APB, Robyn PJ, Singh R. Towards greater equity : a special focus on health.
384 Cameroon economic update; issue no. 6. Washington, D.C.: World Bank Group Jan 2013.
385 Available from: [http://documents.worldbank.org/curated/en/439211468224677542/Towards-](http://documents.worldbank.org/curated/en/439211468224677542/Towards-greater-equity-a-special-focus-on-health)
386 [greater-equity-a-special-focus-on-health](http://documents.worldbank.org/curated/en/439211468224677542/Towards-greater-equity-a-special-focus-on-health). Accessed 12 Jul 2021.
- 387

Women of childbearing age
(15-49) surveyed;
N = 13 527 (unweighted)

Women excluded;
n= 1 054(unweighted)

Women with at least a live
birth in 5 years preceding
the survey;
n = 6 463 (unweighted)

Women excluded;
n= 1 064 (unweighted)


Women with complete data
on our key variables;
n = 5 409 (unweighted)

Final sample size;
n = 5 409 (unweighted)
n = 5 528 (weighted)


medRxiv preprint doi: <https://doi.org/10.1101/2022.10.12.22281001>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.12.22281001>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Figure



medRxiv preprint doi: <https://doi.org/10.1101/2022.10.12.22261001>; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure